6-1-1-6　ⓔ文献

  1. Miller WL, Auchus RJ: The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev, 2011; 32: 81–151.

  2. Dunn, AJ: Cytokine activation of the HPA axis. Ann NY Acad Sci, 2000; 917: 608–617.

  3. Spiga F, Walker JJ, et al: HPA axis–rhythms. Compr Physiol, 2014; 4: 1273–1298.

  4. Talaber G, Jondal M, et al: Extra–adrenal glucocorticoid synthesis: immune regulation and aspects on local organ homeostasis. Mol Cell Endocrinol, 2013; 380: 89–98.

  5. Pemberton PA, Stein PE, et al: Hormone binding globulins undergo serpin conformational change in inflammation. Nature, 1988; 336: 257–258.

  6. Vandevyver S, Dejager L, et al: On the trail of the glucocorticoid receptor: into the nucleus and back. Traffic, 2012; 13: 364–374.

  7. Strahle U, Klock G, et al: DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. Proc Natl Acad Sci USA, 1987; 84: 7871–7875.

  8. Luisi BF, Xu WX, et al: Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature, 1991; 352: 497–505.

  9. Ratman D, Vanden Berghe W, et al: How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol Cell Endocrinol, 2013; 380: 41–54.

  10. Diamond MI, Miner JN, et al: Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science, 1990; 249: 1266–1272.

  11. Woodward MJ, de Boer J, et al: Tnfaip8 is an essential gene for the regulation of glucocorticoid–mediated apoptosis of thymocytes. Cell Death Differ, 2010; 17: 316–323.

  12. 名和田　新：ステロイドの歴史．Mod Physician, 2009; 29: 560–562.

  13. 田中廣壽：ステロイドの作用機序．Mod Physician, 2009; 29: 563–568.

  14. 川合眞一：ステロイドの種類．Mod Physician, 2009; 29: 569–572.

  15. 針谷正祥：ステロイドと他剤との相互作用．Mod Physician, 2009; 29: 573–576.

  16. Cain DW, Cidlowski JA: Immune regulation by glucocorticoids. Nat Rev Immunol, 2017; 17: 233–247.

  17. Hahn BH, McMahon MA, et al: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken), 2012; 64: 797–808.

  18. Walsh M, Merkel PA, et al: Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: A meta–analysis. Arthritis Care Res (Hoboken), 2010; 62: 1166–1173.

  19. Buttgereit F, Straub RH, et al: Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum, 2004; 50: 3408–3417.

  20. Smolen JS, Landewé RBM, et al: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis, 2020. pii: annrheumdis-2019-216655. doi: 10. 1136/annrheumdis-2019-216655.

  21. Duru N, van der Goes MC, et al: EULAR evidence–based and consensus-based recommendations on the management of medium to high–dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis, 2013; 72: 1905–1913.

  22. Boldizsar F, Talaber G, et al: Emerging pathways of non–genomic glucocorticoid (GC) signalling in T cells. Immunobiology, 2010; 215: 521–526.

  23. Herold MJ, McPherson KG, et al: Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci, 2006; 63: 60–72.

  24. Park–Wyllie L, Mazzotta P, et al: Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta–analysis of epidemiological studies. Teratology, 2000; 62: 385–392.

  25. Beitins IZ, Bayard F, et al: The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr, 1972; 81: 936–945.

  26. Anderson GG, Rotchell Y, et al: Placental transfer of methylprednisolone following maternal intravenous administration. Am J Obstet Gynecol, 1981; 140: 699–701.

  27. Blanford AT, Murphy BE: In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol, 1977; 127: 264–267.

  28. Ballard PL, Granberg P, et al: Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest, 1975; 56: 1548–1554.

  29. Ost L, Wettrell G, et al: Prednisolone excretion in human milk. J Pediatr, 1985; 106: 1008–1011.

  30. Gaffo A, Saag KG, et al: Treatment of rheumatoid arthritis. Am J Health Syst Pharm, 2006; 63: 2451–2465.

  31. Angeli A, Guglielmi G, et al: High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross–sectional outpatient study. Bone, 2006; 39: 253–259.

  32. Curtis JR, Westfall AO, et al: Population–based assessment of adverse events associated with long–term glucocorticoid use. Arthritis Rheum, 2006; 55: 420–426.

  33. Wolfe F, Caplan L, et al: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, diseasemodifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum, 2006; 54: 628–634.

  34. Franklin J, Lunt M, et al: Risk and predictors of infection leading to hospitalisation in a large primary–care–derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis, 2007; 66: 308–312.

  35. Schneeweiss S, Setoguchi S, et al: Antitumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum, 2007; 56: 1754–1764.

  36. van Staa TP, Leufkens HG, et al: The epidemiology of corticosteroidinduced osteoporosis: a meta–analysis. Osteoporos Int, 2002; 13: 777–787.

  37. Kanis JA, Stevenson M, et al: A meta–analysis of prior corticosteroid use and fracture risk. J Bone Miner Res, 2004; 19: 893–899.

  38. Natsui K, Tanaka K, et al: High–dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int, 2006; 17: 105–108.

  39. Steinbuch M, Youket TE, et al: Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int, 2004; 15: 323–328.

  40. 日本骨代謝学会：ステロイド性骨粗鬆症の管理と治療ガイドライン2014年改訂版．

  41. Suzuki Y, Nawata H, et al: Guidelines on the management and treatment of glucocorticoid–induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab, 2014; 32: 337–350.

  42. Chrousos GP, Kino T: Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress, 2007; 10: 213–219.

  43. Brown ES, Beard L, et al: Effect of two prednisone exposures on mood and declarative memory. Neurobiol Learn Mem, 2006; 86: 28–34.

  44. Esteban NV, Loughlin T, et al: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab, 1991; 72: 39–45.

  45. Cooper MS, Stewart PM: Corticosteroid insufficiency in acutely ill patients. N Engl J Med, 2003; 348: 727–734.